BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8212988)

  • 1. Pulsatile luteinizing hormone secretion during the first and the fourth cycle on two different oral contraceptives containing gestodene.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):229-36. PubMed ID: 8212988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of levonorgestrel, desogestrel and gestodene on the pulsatile release of luteinizing hormone in oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    Gynecol Endocrinol; 1993 Sep; 7(3):191-200. PubMed ID: 8291457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of action of a new low-dosed combined oral contraceptive.
    Dericks-Tan JS; Schneider K; Taubert HD
    Arch Gynecol; 1980; 229(2):107-14. PubMed ID: 6768343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of oral contraceptives on integrated secretion of gonadotropins.
    Dericks-Tan JS; Gudacker V; Taubert HD
    Contraception; 1992 Oct; 46(4):369-77. PubMed ID: 1486775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
    Elomaa K; Lähteenmäki P
    Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The response of the pituitary-ovarian axis to pulsatile administration of gonadotropin-releasing hormone in long-term oral contraceptive users.
    Hemrika DJ; Slaats EH; Schoemaker J
    Am J Obstet Gynecol; 1994 Feb; 170(2):462-8. PubMed ID: 8116698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
    Scott JA; Brenner PF; Kletzky OA; Mishell DR
    Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene.
    Thomas K; Vankrieken L
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 2):1404-10. PubMed ID: 2121037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.